MediWound Ltd.
MDWD · NASDAQ
Market closed$14.60$-0.010000 (-0.07%)After hours $14.99 · +2.67%
Chart data is refreshing.
Key statistics
Previous close$14.60
Open$14.55
Day high$14.77
Day low$14.49
52-week high$21.11
52-week low$13.54
Market cap158.59M
Volume60.75K
Average volume87.60K
P/E ratio-6.46
Forward P/E—
EPS-2.26
Dividend yield0.00%
Market context
Why it moved
MDWD experienced a marginal decline today, likely reflecting routine profit-taking or low trading volume with no significant company-specific catalysts driving notable price action.
What is happening
Recent company-specific developments and publisher coverage.
Pluang · May 29, 2026Industrial Alliance lowers MediWound price targ...Moomoo · May 29, 2026A. G. P. Maintains MediWound(MDWD.US) With Buy Rating, Cuts Target Price to $22Quiver Quantitative · May 27, 2026MEDIWOUND ($MDWD) Releases Q1 2026 EarningsQuiver Quantitative · April 13, 2026MediWound Highlights U.S. Expert Consensus Supporting EscharEx® Strategy for Chronic Wound DebridementInvesting.com · April 13, 2026MediWound highlights consensus supporting debridement strategySimply Wall Street · January 14, 2026We Think MediWound (NASDAQ:MDWD) Can Afford To Drive Business GrowthQuiver Quantitative · September 29, 2025MediWound Ltd. Announces $30 Million Registered Direct Offering of Ordinary SharesCision News · July 15, 2024Mölnlycke[®] Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd Benzinga · May 28, 2026Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $32 Mt Newswire · May 28, 2026Oppenheimer Adjusts MediWound Price Target to $32 From $33, Maintains Outperform Rating Benzinga · May 27, 2026MediWound Reports Q1 2026 Results: Full Earnings Call Transcript Benzinga · May 27, 2026MediWound Affirms FY2026 Sales Guidance of $24.000M-$26.000M vs $24.759M Est Benzinga · May 27, 2026MediWound Q1 EPS $(0.23) Beats $(0.64) Estimate, Sales $1.475M Miss $3.117M Estimate Benzinga · April 7, 2026MediWound Showcases New Wound Healing Data Across 3 Global Conferences, EscharEx Study Results Back Late-Stage Trials And Expansion Into Diabetic Ulcers Benzinga · March 5, 2026MediWound Affirms FY2028 Sales Guidance of $50.000M-$55.000M Benzinga · March 5, 2026MediWound Affirms FY2027 Sales Guidance of $32.000M-$35.000M